Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06686394 · ClinicalTrials.gov registry record · Phase 1

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

A Phase 1 study of Breast Cancer and Breast Neoplasms, sponsored by Merck Sharp & Dohme.

Recruiting
Registry status
Phase 1
Development phase
81
Enrollment target
17
Study locations

NCT06686394 is a Phase 1 study of Breast Cancer and Breast Neoplasms that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 81 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 17 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06686394, a Phase 1 study of Breast Cancer and Breast Neoplasms, is actively recruiting participants, sponsored by Merck Sharp & Dohme.

RECRUITING
Registry status
Phase 1
Development phase
81 participants
Enrollment target
17
Study locations

Study Summary

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment

Conditions Studied

Breast Cancer Breast Neoplasms

Interventions

  • BIOLOGICAL Trastuzumab
  • BIOLOGICAL Patritumab deruxtecan
  • BIOLOGICAL Pertuzumab
  • BIOLOGICAL Trastuzumab Biosimilar
  • BIOLOGICAL Tucatinib

Study Locations (17)

Other

  • Rambam Health Care Campus ( Site 0011) - Haifa
  • Rabin Medical Center ( Site 0012) - Petah Tikva
  • Sheba Medical Center ( Site 0010) - Ramat Gan
  • Seoul National University Hospital ( Site 0030) - Seoul
  • Asan Medical Center ( Site 0031) - Seoul

Ontario

  • Kingston General Hospital ( Site 0061) - Kingston
  • Princess Margaret Cancer Centre ( Site 0001) - Toronto

Quebec

  • Centre Hospitalier de l'Université de Montréal ( Site 0004) - Montreal
  • Jewish General Hospital ( Site 0003) - Montreal

Massachusetts

  • Dana-Farber Cancer Institute ( Site 0050) - Boston

New Jersey

  • Rutgers Cancer Institute of New Jersey ( Site 0052) - New Brunswick

South Carolina

  • Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053) - Greenville

Virginia

  • Inova Schar Cancer Institute ( Site 0051) - Fairfax

Aichi-ken

  • Nagoya City University Hospital ( Site 0020) - Nagoya

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2025-02-26
Est. Completion 2030-04-18
Phase Phase 1

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06686394

The ClinicalTrials.gov registry entry for NCT06686394 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.

NCT06686394 reports 17 study locations spanning 11 distinct geographic areas - top geographies include Other, Ontario, Quebec.

Frequently Asked Questions

What is clinical trial NCT06686394 about?

NCT06686394 is a clinical study titled "Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)". Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety ...

What is the current status of trial NCT06686394?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2025-02-26. Estimated completion is 2030-04-18.

What conditions does trial NCT06686394 study?

This clinical trial studies the following conditions: Breast Cancer, Breast Neoplasms.

What interventions are being tested in trial NCT06686394?

The interventions under investigation include: Trastuzumab (BIOLOGICAL), Patritumab deruxtecan (BIOLOGICAL), Pertuzumab (BIOLOGICAL), Trastuzumab Biosimilar (BIOLOGICAL), Tucatinib (BIOLOGICAL).

Who is sponsoring clinical trial NCT06686394?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06686394 being conducted?

This trial has 17 study locations across Massachusetts, New Jersey, South Carolina, Virginia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Breast Neoplasms

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.